Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
India’s Sun Pharmaceutical Industries Ltd is in talks to buy Swedish drugmaker Meda AB for $5 billion-$6 billion to boost its generics business in developed markets, two sources with direct knowledge of the process said. Meda makes specialty products, over the counter drugs and branded generics - the same areas of focus as Sun Pharma. Meda had sales of about 13 billion Swedish crowns ($1.98 billion) in 2012 and has a market value of roughly $3.7 billion. Mumbai-based Sun Pharma is India’s most valuable drugmaker, with a market capitalisation of roughly $20 billion, and has made several acquisitions in recent years, although a deal for Meda would be its largest. Sun Pharma had cash of 40.6 billion rupees ($721.84 million) at the end of March. “Sun Pharma is in an extremely sweet spot with a low amount of debt and strong organic business growth,” said Jagannadham Thunuguntla, equity head at SMC Global Securities in New Delhi.
Help employers find you! Check out all the jobs and post your resume.
